Last reviewed 2026-04-22 · How we verify

Double antiplatelet therapy

Double antiplatelet therapy combines two antiplatelet agents to inhibit platelet aggregation through different mechanisms, reducing thrombotic events.

Double antiplatelet therapy combines two antiplatelet agents to inhibit platelet aggregation through different mechanisms, reducing thrombotic events. Used for Acute coronary syndrome, Percutaneous coronary intervention with stent placement, Secondary prevention of myocardial infarction.

At a glance

Mechanism of action

This is a therapeutic regimen rather than a single drug, typically combining aspirin (which inhibits cyclooxygenase and thromboxane A2 production) with a P2Y12 receptor antagonist (such as clopidogrel, prasugrel, or ticagrelor) to provide dual inhibition of platelet activation and aggregation. The combination provides superior antithrombotic efficacy compared to monotherapy, particularly in acute coronary syndromes and after percutaneous coronary intervention.

Approved indications

• Acute coronary syndrome
• Percutaneous coronary intervention with stent placement
• Secondary prevention of myocardial infarction
• Stroke prevention in high-risk patients

Common side effects

• Bleeding
• Gastrointestinal bleeding
• Dyspepsia
• Bruising
• Intracranial hemorrhage

Key clinical trials

• A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (PHASE3)
• Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
• Comparing Two PFO Closure Devices in Adults With Previous Stroke or TIA (NA)
• PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
• Randomized Active-Controlled Trial Evaluating Fexuprazan (Fexuclue Tab) for Prevention Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy After Coronary Intervention (NA)
• The 10-Year Extended Follow-up of the DACAB Trial
• Chaigui Longmu Ejiao Paste for Ischemic Heart Disease (PHASE2)
• Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.